Blinding retinal disease due to tissue hypoxia remains a significant unmet need impacting just under 1 million patients per year stemming from conditions including artery and vein occlusions to diabetic retinopathy. ReVive Biotechnology, Inc. is dedicated to developing nano-carriers for the effective treatment of hypoxic conditions. Our mission is to improve visual outcomes and quality of life for patients by targeted/immediate delivery of oxygen where it's most needed.
Striving To Treat Blinding Retinal Conditions
ReVive Biotechnology is a diverse, multidisciplinary, and friendly team motivated to better lives through the advancement of clinical therapeutics. Based in Research Park at the University of Illinois, Urbana-Champaign, the team has access to state-of-the-art laboratories and facilities to carry out their research.
What We Do
With a goal of improving oxygen delivery to hypoxic tissues by utilizing innovative nanotechnology, research and development is currently focused on treatment for central retinal artery occlusion (CRAO) with potential future applications for additional ocular ischemic conditions. Pre-clinical studies have advanced through proof of concept and the team is now working through the regulatory process to achieve FDA approval for this revolutionary therapeutic.
Hypoxia or low oxygen levels is a significant cause of damage to important ocular tissues. When this occurs in the retina it often leads to blindness. ReVive Biotechnology’s innovative oxygen nano delivery system will improve oxygenation of hypoxic retinal tissue. Supported in part by the National Science Foundation, ReVive has shown promising results in animal models which demonstrate that it can preserve retinal tissue structure, leading to improved function (visual outcomes). The nano-carrier technology is currently undergoing preclinical testing. Focused on the initial pathway for treatment of central retinal artery occlusion, a blinding rare retinal disease that has no current effective treatment, ReVive is working through the regulatory pathway with the US Food and Drug Administration (FDA) and is poised to reach human trials.
Lead Program: Retinal Tissue Hypoxia
Central retina artery occlusion (CRAO)
Branch retinal artery occlusion (BRAO)
Retinal Vein Occlusion (RVO)
Diabetic Retinopathy (DR)
Ischemic Optic Neuropathy (ION)